Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
deltaG Ketones is a life sciences company that develops and commercializes a proprietary ketone ester, (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, originally developed through a collaboration between the University of Oxford and the National Institutes of Health (NIH). The company's technology provides a highly efficient way to elevate blood ketone levels without the need for restrictive ketogenic diets, offering a potent fuel source for the brain and muscles. deltaG's products are used by elite athletes for performance and recovery, while the molecule is simultaneously being investigated in numerous clinical trials for therapeutic applications in metabolic, cardiovascular, and neurological health. The company focuses on bridging the gap between high-performance nutrition and medical metabolic therapy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on deltaG Ketones.